Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muhammad Asad

Interventional Cardiology Hermitage, TN Medical Doctor

NPI 1275536468 CMS profile 57294

5651 Frist Blvd Ste 603, Hermitage, TN 37076

Open in the dashboard

General payments

$13,593

669 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Muhammad Asad of Hermitage, TN is reported in the CMS Open Payments database as having received $13,593 across 669 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,033 137
2024 General $2,081 89
2023 General $2,726 118
2022 General $2,156 123
2021 General $1,061 64
2020 General $1,161 51
2019 General $1,376 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muhammad Asad
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Muhammad Asad were reported at $3,033. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Muhammad Asad Interventional Cardiology median Middle half National median
2019 $1,376 $1,097 $329–$3,048 $163
2020 $1,161 $473 $161–$1,480 $114
2021 $1,061 $677 $233–$1,827 $132
2022 $2,156 $978 $333–$2,724 $149
2023 $2,726 $1,136 $382–$2,986 $160
2024 $2,081 $1,181 $395–$3,326 $164
2025 $3,033 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,606 72 payments
  2. E.R. Squibb & Sons, L.L.C. $1,084 80 payments
  3. Pfizer Inc. $919 64 payments
  4. Novo Nordisk Inc $908 30 payments
  5. Boston Scientific Corporation $887 38 payments
  6. Janssen Pharmaceuticals, Inc $886 59 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $827 41 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $602 23 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $553 33 payments
  10. AstraZeneca Pharmaceuticals LP $524 31 payments
  11. Other $4,796 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,491 662 payments
  2. Education $101 7 payments
Products named General payments · program years 2019–2025
  1. Repatha $1,420 61 payments
  2. XARELTO $886 59 payments
  3. ELIQUIS $688 58 payments
  4. VYNDAQEL $678 45 payments
  5. LifeVest $553 33 payments
  6. Kerendia $494 17 payments
  7. UPTRAVI $479 18 payments
  8. JARDIANCE Diabetes $441 21 payments
  9. JARDIANCE Diabetes $385 20 payments
  10. CAMZYOS $381 21 payments
  11. Other $7,879 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

6,456

Median for Interventional Cardiology: 2,236

Drug cost

$1,183,743

Median for Interventional Cardiology: $380,412

Branded share of claims

24.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 299 $317,633
Xarelto Rivaroxaban Brand 171 $191,872
Jardiance Empagliflozin Brand 157 $166,564
Ozempic Semaglutide Brand 78 $115,897
Entresto Sacubitril/Valsartan Brand 70 $91,993
Repatha Sureclick Evolocumab Brand 108 $90,086
Wegovy Semaglutide Brand 21 $29,658
Farxiga Dapagliflozin Propanediol Brand 21 $26,376
Verquvo Vericiguat Brand 22 $23,228
Mounjaro Tirzepatide Brand 14 $16,641

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$160,032

Medicare's payments for the services billed

Medicare patients

1,441

Average age 76

Services billed

3,439

789 women, 652 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 55%
Chronic kidney disease 41%
Diabetes 40%
Atrial fibrillation 40%
Heart failure 35%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $180
$180 — —
VYNDAQEL
  • PFIZER INC. $174
$174 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $112
$112 — —
RYBELSUS
  • Novo Nordisk Inc $105
$105 — —
Ozempic
  • Novo Nordisk Inc $105
$105 78 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

669 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record